Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

LCSB coordinates European project on Parkinson’s research

03.12.2015

The Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg is coordinating an EU project for research into new active compounds against Parkinson’s disease (PD). SysMedPD (Systems Medicine of Mitochondrial Parkinson’s Disease) is the name of the project that just started with the involvement of five universities and three companies from Luxembourg, Germany, Ireland, the Netherlands and UK. The European Union is funding the researchers of this consortium with a total of 5.9 million euros.

With this funding, they will be developing novel techniques by which to identify and research into active compounds against PD. They will furthermore be advancing drug candidates towards their medical application.


From left: Prof. Jens Schwamborn (head of the LCSB group Development and Cell Biology), Prof. Rudi Balling (LCSB director and coordinator of SysMedPD) und Dr Ronan Fleming (Systems Biochemist

scienceRELATIONS / Universität Luxemburg

“Universities and biopharmaceutical companies complement each other’s expertise ideally in SysMedPD,” says Prof. Rudi Balling, LCSB director and coordinator of SysMedPD. “This creates optimal conditions in which to progress a good deal further in developing diagnoses and therapies for Parkinson’s disease.”

Parkinson’s disease is a gradually progressive disease of human nerve tissue, resulting among other things in muscle tremors and muscle rigidity. The mitochondria of nerve cells are often causally involved in the onset – mitochondria being the power plants of cells, in which biochemical reactions provide energy for cellular metabolic processes.

“We estimate that in about ten to twenty percent of all Parkinson’s patients, their mitochondria do not function properly,” says senior LCSB scientist Dr Ronan Fleming, who is significantly involved in the conception and coordination of SysMedPD. “In order to better diagnose, heal or at least effectively curb the progression of Parkinson’s disease, we must understand this dysfunction of mitochondria in detail.”

The researchers within SysMedPD are first concentrating on such patterns of PD in which the mitochondria are damaged by mutations in individual genes. “Later, the results can then be carried over to patient groups in which multiple genes and environmental factors are involved in the onset of PD,” adds Dr Fleming.

The SysMedPD consortium will tackle this task with different approaches: “At the LCSB, we place emphasis on developing new, computational models by which we can better depict the processes going on inside mitochondria,” Ronan Fleming says. Prof. Jens Schwamborn, head of the LCSB group Development and Cell Biology, describes a complementary approach: “We must verify any computational predictions using experiments. Therefore, in the scope of this EU project, we will also employ advanced cellular models, where skin samples obtained from Parkinson’s disease patients are reprogrammed into living human nerve cells.”

To ensure the research results obtained within SysMedPD are translated into application as quickly as possible, the consortium also has biopharmaceutical companies on board. Their areas of involvement are test development for new active compounds and identification of active compounds.

“The project is organised such that the insights that we and the other academic partners gain will complement those of the companies involved very well,” says Prof. Rudi Balling. “With this close connection between public and private research, we can ensure the EU funding, firstly, is employed optimally in the interest of the PD patients and, secondly, will generate economic stimuli. These are important objectives of the EU that we will fulfil here.”

The SysMedPD partners:
- Germany: University of Lübeck (Prof. Christine Klein), EURICE – European Research and Project Office GmbH (Corinna Hahn)
- Ireland: Maynooth University (Dr Niall Finnerty)
- Luxembourg: University of Luxembourg (Prof. Rudi Balling, Dr Ronan Fleming, Prof. Jens Schwamborn)
- Netherlands: Leiden University (Prof. Thomas Hankemeier), Khondrion BV (Prof. Jan Smeitink), Mimetas BV (Dr Paul Vulto)
- Great Britain: University College London (Prof. Anthony Schapira)

Weitere Informationen:

http://www.uni.lu/lcsb - Homepage of the Luxembourg Centre for Systems Biomedicine

Britta Schlüter | Universität Luxemburg - Université du Luxembourg

More articles from Health and Medicine:

nachricht New discoveries predict ability to forecast dementia from single molecule
12.12.2018 | UT Southwestern Medical Center

nachricht Pain: Perception and motor impulses arise in the brain independently of one another
12.12.2018 | Technische Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Lethal combination: Drug cocktail turns off the juice to cancer cells

A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.

The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...

Im Focus: New Foldable Drone Flies through Narrow Holes in Rescue Missions

A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.

Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...

Im Focus: Topological material switched off and on for the first time

Key advance for future topological transistors

Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...

Im Focus: Researchers develop method to transfer entire 2D circuits to any smooth surface

What if a sensor sensing a thing could be part of the thing itself? Rice University engineers believe they have a two-dimensional solution to do just that.

Rice engineers led by materials scientists Pulickel Ajayan and Jun Lou have developed a method to make atom-flat sensors that seamlessly integrate with devices...

Im Focus: Three components on one chip

Scientists at the University of Stuttgart and the Karlsruhe Institute of Technology (KIT) succeed in important further development on the way to quantum Computers.

Quantum computers one day should be able to solve certain computing problems much faster than a classical computer. One of the most promising approaches is...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

ICTM Conference 2019: Digitization emerges as an engineering trend for turbomachinery construction

12.12.2018 | Event News

New Plastics Economy Investor Forum - Meeting Point for Innovations

10.12.2018 | Event News

EGU 2019 meeting: Media registration now open

06.12.2018 | Event News

 
Latest News

New discoveries predict ability to forecast dementia from single molecule

12.12.2018 | Health and Medicine

CCNY-Yale researchers make shape shifting cell breakthrough

12.12.2018 | Physics and Astronomy

Pain: Perception and motor impulses arise in the brain independently of one another

12.12.2018 | Health and Medicine

VideoLinks
Science & Research
Overview of more VideoLinks >>>